ONTARGET: Primary outcome results

1
ONTARGET Primary outcome results
N 25,620 with vascular disease or high-risk
diabetes
0.20
0.15
Cumulativehazard ratio
0.10
0.05
0.00
0
1
2
3
4
5
Follow-up (years)
Ramipril
Telmisartan
Telmisartan plus ramipril
Ongoing Telmisartan Alone and in Combination with
Ramipril Global Endpoint Trial
ONTARGET Investigators. N Engl J Med.
20083581547-59.
2
ONTARGET Incidence of primary outcome and
components
Patients could have multiple events in this
category CV
cardiovascular, HF heart failure, MI
myocardial infarction, RR risk ratio.
ONTARGET Investigators. N Engl J Med.
20083581547-59.
3
ONTARGET Secondary outcomes
ONTARGET Investigators. N Engl J Med.
20083581547-59.
P lt 0.001